Cargando…
Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer
Triple negative breast cancer (TNBC) is a cluster of heterogeneous diseases, all of them sharing the lack of expression of estrogen and progesterone receptors and HER2 protein. They are characterized by different biological, molecular and clinical features, including a poor prognosis despite the inc...
Autores principales: | Mancini, Patrizia, Angeloni, Antonio, Risi, Emanuela, Orsi, Errico, Mezi, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276962/ https://www.ncbi.nlm.nih.gov/pubmed/25347122 http://dx.doi.org/10.3390/cancers6042187 |
Ejemplares similares
-
Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer
por: Mezi, Silvia, et al.
Publicado: (2021) -
The clinical promise of immunotherapy in triple-negative breast cancer
por: Vikas, Praveen, et al.
Publicado: (2018) -
Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
por: Wang, Xiaoxiao, et al.
Publicado: (2023) -
Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
por: Saravia, César H, et al.
Publicado: (2019) -
Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
por: Ryu, Won-Ji, et al.
Publicado: (2021)